Amsterdam, the Netherlands, 20 January 2016. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercializing the Kaleido insulin pump system for diabetes patients. The syndicate, led by LSP with participation from existing investor INKEF will invest EUR 10 million. The funding will support European commercialization of the Kaleido system and preparations for US market entry. As part of the financing, Anne Portwich and Jörg Neermann, both partners, LSP, will join ViCentra’s supervisory board.
Driven by ViCentra’s belief in the power of innovative healthcare products that put the people who use them first and a desire to be meaningfully different, Kaleido aims to reduce the impact that diabetes can have on daily life. Utilizing Bluetooth wireless technology, Kaleido will infuse color and choice into the market, networking its hybrid patch pumps and handsets into a broader family of easy-to-use products and data services to create a customer-focused, integrated diabetes support service. Setting its sights on expanding insulin pump usage by appealing to both first time and experienced insulin pump users, Kaleido will launch in selected European territories over the course of 2016.
About ViCentra
ViCentra was founded in 2013 with investments from Dutch investors Health Innovations and INKEF. Based in Utrecht, the Netherlands, ViCentra brings together a team of people that believe in keeping things simple. That if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. ViCentra are creating healthcare products with this philosophy firmly in mind. We don’t design for patients – we design for people. More information can be found at www.vicentra.com and www.hellokaleido.com.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. LSP will participate with two funds in this financing, the LSP Health Economics Fund and the LSP 5 Fund. For more information, please visit www.lspvc.com.
Anne Portwich, PhD
Partner LSP
+31 20 6645500